The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Open accessAbstract
Background: Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A (IL-17A) activity leads to a protumor microenvironment, dependent on its ability to induce the production of inflammatory mediators, mobilize myeloid cells and reshape the tumor environment. In the present study, we aimed to investigate the role of IL-17A in resistance to antitumor immunity and to explore the feasibility of anti-IL-17A combined with anti-PD-1 therapy in MSS CRC murine models. Methods: The expression of programmed cell death-ligand 1 (PD-L1) and its regulation by miR-15b-5p were investigated in MSS CRC cell lines and tissues. The effects of miR-15b-5p on tumorigenesis and anti-PD-1 treatment sensitivity were verified both in vitro and in colitis-associated cancer (CAC) and APC min/+ murine models. In vivo efficacy and mechanistic studies were conducted using antibodies targeting IL-17A and PD-1 in mice bearing subcutaneous CT26 and MC38 tumors. Results: Evaluation of clinical pathological specimens confirmed that PD-L1 mRNA levels are associated with CD8+ T cell infiltration and better prognosis. miR-15b-5p was found to downregulate the expression of PD-L1 at the protein level, inhibit tumorigenesis and enhance anti-PD-1 sensitivity in CAC and APC min/+ CRC models. IL-17A led to high PD-L1 expression in CRC cells through regulating the P65/NRF1/miR-15b-5p axis. Combined IL-17A and PD-1 blockade had efficacy in CT26 and MC38 tumors, with more cytotoxic T lymphocytes cells and fewer myeloid-derived suppressor cells in tumors. Conclusions: IL-17A increases PD-L1 expression through the p65/NRF1/miR-15b-5p axis and promotes resistance to anti-PD-1 therapy. Blocking IL-17A improved the efficacy of anti-PD-1 therapy in MSS CRC murine models. IL-17A might serve as a therapeutic target to sensitize patients with MSS CRC to ICI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Profiling Tumor Infiltrating Immune Cells with CIBERSORT
Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M., & Alizadeh, A. A. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7493-1_12 · Cited by 3,874
Self-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Immune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., & Fridman, W.-H. (2010) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,087
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890 · cited 14×
“44 45 Overall, our discovery of the effects of miR- 15b-5p, combined with the PTM mediators of PD-L1, provided potential explanations for why the clinical significance of PD-L1 protein is not consistent with that of its mRNA in MSS CRC. Interferons are not the only inflammatory stimuli that have been linked to PD-L1 e…”
InfluentialIdentification of CMTM6 and CMTM4 as PD-L1 protein regulators
Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697
Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608 · cited 2×
“17 A recent report also confirmed that IL-17 signaling inhibits the production of CXCL9/10 chemokines to reduce the infiltration of CTLs and Tregs into the CRC milieu.”
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
Emerging cytokine networks in colorectal cancer
West, N. R., McCuaig, S., Franchini, F., & Powrie, F. (2015) · Nature Reviews Immunology · doi:10.1038/nri3896 · Cited by 396
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Hsu, J.-M., Li, C.-W., Lai, Y.-J., & Hung, M.-C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1892 · Cited by 286
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
Mlecnik, B., Van den Eynde, M., Bindea, G., Church, S. E., Vasaturo, A., Fredriksen, T., Lafontaine, L., Haicheur, N., Marliot, F., Debetancourt, D., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx123 · Cited by 250
Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aay0555 · Cited by 245
Liu, C., Yao, Z., Wang, J., Zhang, W., Yang, Y., Zhang, Y., Qu, X., Zhu, Y., Zou, J., Peng, S., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0460-0 · Cited by 230
Self-citationHigh prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas
Le Gouvello, S., Bastuji-Garin, S., Aloulou, N., Mansour, H., Chaumette, M.-T., Berrehar, F., Seikour, A., Charachon, A., Karoui, M., Leroy, K., et al. (2008) · Gut · doi:10.1136/gut.2007.123794 · Cited by 214
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Esfahani, K., & Miller, W. H. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703047 · Cited by 200
Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer
Amicarella, F., Muraro, M. G., Hirt, C., Cremonesi, E., Padovan, E., Mele, V, Governa, V, Han, J., Huber, X., Droeser, R. A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310016 · Cited by 189
Evolutionary history of human colitis-associated colorectal cancer
Baker, A.-M., Cross, W., Curtius, K., Al Bakir, I., Choi, C.-H. R., Davis, H. L., Temko, D., Biswas, S., Martinez, P., Williams, M. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316191 · Cited by 161
Kao, S., Cheng, Y. Y., Williams, M., Kirschner, M. B., Madore, J., Lum, T., Sarun, K. H., Linton, A., McCaughan, B. C., Klebe, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.024 · Cited by 152
Chen, J., Ye, X., Pitmon, E., Lu, M., Wan, J., Jellison, E. R., Adler, A. J., Vella, A. T., & Wang, K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0757-z · Cited by 144
IL-17 and colorectal cancer: From carcinogenesis to treatment
Razi, S., Noveiry, B. B., Keshavarz‐Fathi, M., & Rezaei, N. (2019) · Cytokine · doi:10.1016/j.cyto.2018.12.021 · Cited by 141
Dual biological effects of the cytokines interleukin-10 and interferon-γ
Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138
Tumor Infiltrating T Lymphocytes in Colorectal Cancer
Koch, M., Beckhove, P., den Winkel, J. O., Autenrieth, D., Wagner, P., Nummer, D., Specht, S., Antolovic, D., Galindo, L., Schmitz-Winnenthal, F. H., et al. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000247058.43243.7b · Cited by 131
Hersom, M., & Jørgensen, J. T. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000460 · Cited by 130
Liu, C., Yao, Z., Wang, J., Zhang, W., Yang, Y., Zhang, Y., Qu, X., Zhu, Y., Zou, J., Peng, S., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0506-3 · Cited by 122
Self-citationMechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
Knudson, K. M., Hicks, K. C., Alter, S., Schlom, J., & Gameiro, S. R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0551-y · Cited by 120
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Conroy, J. M., Pabla, S., Nesline, M., Glenn, S. T., Papanicolau‐Sengos, A., Burgher, B., Andreas, J., Giamo, V., Wang, Y., Lenzo, F. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0489-5 · Cited by 97
SIRT1 suppresses colorectal cancer metastasis by transcriptional repression of miR-15b-5p
Sun, L., Zhi, Z., Chen, L., Zhou, Q. Y., Li, X., Gan, W.-J., Chen, S., Yang, M., Liu, Y., Shen, T., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.001 · Cited by 93
Pekow, J. R., Meckel, K. R., Dougherty, U., Huang, Y., Chen, X., Almoghrabi, A., Mustafi, R., Ayaloglu-Butun, F., Deng, Z., Haider, H. I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0171 · Cited by 88
Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer.
Kettunen, H., Kettunen, A., & Rautonen, N. (2003) · PubMed · Cited by 76
Llosa, N. J., Luber, B. S., Tam, A. J., Smith, K. N., Siegel, N. M., Awan, A. H., Fan, H., Oke, T. F., Zhang, J., Domingue, J. C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0114 · Cited by 68
Ma, L., Feng, F., Dong, L., Zhang, Z., Duan, M., Liu, L., Shi, J.-Y., Yang, L., Wang, Z., Zhang, S., et al. (2018) · Theranostics · doi:10.7150/thno.28742 · Cited by 67
Self-citationAotsuka, A., Matsumoto, Y., Arimoto, T., Kawata, A., Ogishima, J., Taguchi, A., Tanikawa, M., Sone, K., Mori‐Uchino, M., Tsuruga, T., et al. (2019) · Cancer Science · doi:10.1111/cas.14174 · Cited by 64
Wei, Y., Shi, D., Liang, Z., Liu, Y., Li, Y., Xing, Y., Liu, W., Ai, Z., Zhuang, J., Chen, X., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.034 · Cited by 63
Ji, D., Zhan, T., Li, M., Yao, Y., Jia, J., Yi, H., Qiao, M., Xia, J., Zhang, Z., Ding, H., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.10.015 · Cited by 60
Self-citationNRF-1 is the major transcription factor regulating the expression of the human TOMM34 gene
Blesa, J. R., Prieto-Ruiz, J. Á., Abraham, B. A., Harrison, B. L., Hegde, A. A., & Hernández-Yago, J. (2008) · Biochemistry and Cell Biology · doi:10.1139/o07-151 · Cited by 45
Colitis-accelerated colorectal cancer and metabolic dysregulation in a mouse model
Gao, Y., Li, X., Yang, M. W., Zhao, Q., Liu, X., Wang, G., Lü, X., Wu, Q., Wu, J., Yang, Y., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt135 · Cited by 35
Self-citationColorectal cancer in Crohn’s colitis is comparable to sporadic colorectal cancer
Lennerz, J. K., van der Sloot, K. W. J., Le, L. P., Batten, J. M., Han, J. Y., Fan, K. C., Siegel, C. A., Srivastava, A., Park, D. Y., Chen, J.-H., et al. (2016) · International Journal of Colorectal Disease · doi:10.1007/s00384-016-2574-x · Cited by 33
Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis
Blauvelt, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1132695 · Cited by 30
Duncan, D. J., Scott, M. L. J., Scorer, P., & Barker, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215393 · Cited by 27
Farlow, S. J., Jerusalmi, A., & Sano, T. (2007) · BMC Biotechnology · doi:10.1186/1472-6750-7-83 · Cited by 9
Mismatch Repair–Proficient Colorectal Cancer: Finding the Right TiME to Respond
Willis, J. A., Overman, M. J., & Vilar, E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1447 · Cited by 6
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
IL-17–induced HIF1α drives resistance to anti–PD-L1 via fibroblast-mediated immune exclusion
Chen, X., Zhao, J., Herjan, T., Hong, L., Liao, Y., Liu, C., Vasu, K., Wang, H., Thompson, A., Fox, P. L., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210693 · Cited by 53
Self-citationThe Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Tria, S. M., Burge, M. E., & Whitehall, V. L. J. (2023) · Cancers · doi:10.3390/cancers15082375 · Cited by 38
Metadata
- Authors
- Liu, C., Liu, R., Wang, B., Lian, J., Yao, Y., Sun, H., Zhang, C., Fang, L., Guan, X., Shi, J., Han, S., Zhan, F., Luo, S., Yao, Y., Zheng, T., & Zhang, Y.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-01
- Volume
- 9
- Issue
- 1
- Pages
- e001895
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3121973410
- Cited by
- 257
- References
- 48
- FWCI
- 13.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.